Genesis Healthcare, Inc. (NYSE:GEN) has made a 96.67% comeback from a 12-month low price of $0.60. It was seen 16.83% higher, changing the price to $1.18, when the closing bell rang on 02/14/2018. At recent session, the prices were hovering between $0.99 and $1.19. This company shares are 145.76% off its target price of $2.9 and the current market capitalization stands at $194.62M. The recent change has given its price a 40.66% lead over SMA 50 and -70.43% deficit over its 52-week high. The stock witnessed 37.21% gains, 27.14% gains and 9.26% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GEN’s volatility during a week at 11.43% and during a month it has been found around 10.05%.
Genesis Healthcare, Inc. (GEN) Top Holders
Institutional investors currently hold around $30 million or 33.9% in GEN stock. Look at its top three institutional owners. Columbia Pacific Advisors, Llc owns $8.24 million in Genesis Healthcare, Inc., which represents roughly 4.24% of the company’s market cap and approximately 27.48% of the institutional ownership. Similar statistics are true for the second largest owner, Hightower Advisors, Llc, which owns 3,289,421 shares of the stock are valued at $3.32 million. The third largest holder is First Washington Corp, which currently holds $3.09 million worth of this stock and that ownership represents nearly 1.59% of its market capitalization.
Genesis Healthcare, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 36 institutional holders increased their position in Genesis Healthcare, Inc. (NYSE:GEN) by some 8,689,064 shares, 33 decreased positions by 2,948,421 and 15 held positions by 18,547,752. That puts total institutional holdings at 30,185,237 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 5,940,765 shares while 17 institutional investors sold out their entire positions totaling 781,048 shares.
Genesis Healthcare, Inc. (NYSE:GEN) Insider Trades
Multiple company employees have indulged in significant insider trading. Genesis Healthcare, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP and Chief Nursing Officer Reifsnyder Joanne Susan has sold 5,269 shares of Genesis Healthcare, Inc. (GEN) in trading session dated Jun. 14, 2017. These shares are worth $9,115 and were traded at $1.73 each. The SEC filing shows that Young Stephen Scott performed a sale of 3,799 shares. The VP and Corporate Controller disposed these shares by way of transaction on Jun. 14, 2017. The company’s shares were given away at $1.73 per share worth to an income of some $6,572 on account of Young Stephen Scott.
SVP and General Counsel, Sherman Michael Scott, sold 3,903 common shares of Genesis Healthcare, Inc. (GEN) in the open market. In a transaction dated Jun. 14, 2017, the shares were put up for sale at an average price of $1.73, raking in a sum of $6,752. After this sale, 510,574 common shares of GEN are directly owned by the insider, with total stake valued at $602,477.
In the transaction dated Jun. 14, 2017, the great number of shares disposed came courtesy the COO; Bach Paul David disposed a total of 6,100 shares at an average price of $1.73, amounting to approximately $10,553. The insider now directly owns 603,271 shares worth $711,860.
Genesis Healthcare, Inc. (GEN) Analyst Guide
Several analysts have released their opinion on Genesis Healthcare, Inc. (NYSE:GEN), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.67 average brokerage recommendation.